The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
Yi Long Wu
No relevant relationships to disclose
Caicun Zhou
No relevant relationships to disclose
Cheng-Ping Hu
No relevant relationships to disclose
Ji Feng Feng
No relevant relationships to disclose
Shun Lu
No relevant relationships to disclose
Yunchao Huang
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Mei Hou
No relevant relationships to disclose
Jian Hua Shi
No relevant relationships to disclose
Kye Young Lee
No relevant relationships to disclose
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Yang Shi
Employment or Leadership Position - Boehringer Ingelheim
Jiongjie Chen
Employment or Leadership Position - Boehringer Ingelheim
Victoria Zazulina
Employment or Leadership Position - Boehringer Ingelheim
Sarayut Lucien Geater
No relevant relationships to disclose